Haemoglobin based oxygen carriers (HBOCs) have applications in wound healing, perfusion of donated transplant organs and ultimately in trauma.
The UK-based SME has, in effect, created microparticles which mimic artificial red blood cells comprised entirely of fatty acids and haemoglobin. These microparticles have the advantage that they are the same order of magnitude as red blood cells and as such do not pass through capillary walls in the same way as other HBOCs in development.
This technology needs further development towards commercialisation and the SME is looking for partners for this programme. They are especially looking for partners with expertise in HBOC development. It is expected that the partnership will take the form of a technical cooperation agreement or IP licence.